BSEBoard Meeting30 Sept 2026 · 30 Sept 2026, 07:29 pm
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Novartis India Ltd · 500672
✦ AI SummaryResults
Novartis India Ltd has scheduled a Board Meeting on 03/11/2026 to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Novartis India Ltd - 500672 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Attachments (1)
📄pdf
Download →
3d633491-dd1c-444c-bde5-1766b633662e.pdf
View document text
Novartis India Limited
September 30, 2026
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip code: 500672
Sub.: Intimation of the meeting of the Board of Directors of Novartis India Limited ('the Company')
and the Closure of Trading Window.
Dear Sir/ Madam,
Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of
Directors of Novartis India Limited ("the Company") is scheduled to be held on Tuesday, November
03, 2026, inter alia, to consider and approve the Unaudited Financial Results of the Company for the
quarter and half year ended September 30, 2026.
Further, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading by Designated
Persons of the Company, read with the applicable provisions of the Securities and Exchange Board
of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the
securities of the Company by Designated Persons/ Insiders/ Connected Persons and their immediate
relatives shall remain closed with effect from October 01, 2026, and shall reopen 48 hours after the
declaration of the aforesaid Financial Results to the Stock Exchange (“BSE Limited”).
The above information is also being made available on the website of the Company at
https://nilpharma.co.in/
You are requested to take note of the above information.
Thank You.
Yours Sincerely,
For Novartis India Limited
Chandni Maru
Company Secretary and Compliance Officer
M. No. A60291
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in